- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | BioAtla, Inc.: BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing | 458 | GlobeNewswire (Europe) | These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with... ► Artikel lesen | |
| BIOATLA Aktie jetzt für 0€ handeln | |||||
| 14.11. | BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch | 9 | Seeking Alpha | ||
| 13.11. | Bioatla Q3 2025: EPS-Prognose erfüllt, Aktie fällt jedoch wegen Liquiditätssorgen | 7 | Investing.com Deutsch | ||
| 13.11. | BioAtla GAAP EPS of -$0.08 beats by $0.22 | 2 | Seeking Alpha | ||
| 13.11. | BioAtla, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.11. | BioAtla, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.11. | What's Next: BioAtla's Earnings Preview | 11 | Benzinga.com | ||
| 07.11. | BioAtla, Inc.: BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas | 179 | GlobeNewswire (Europe) | - Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with... ► Artikel lesen | |
| 20.10. | BioAtla reports promising early data for dual-CAB cancer therapy | 3 | Investing.com | ||
| 03.10. | BioAtla, Inc.: BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 | 5 | GlobeNewswire (USA) | ||
| 22.09. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | BioAtla: JMP bestätigt 'Market Perform'-Rating nach FDA-Zustimmung zum Phase-3-Design | 4 | Investing.com Deutsch | ||
| 09.09. | BioAtla stock holds Market Perform rating at JMP as FDA aligns on Phase 3 design | 2 | Investing.com | ||
| 08.09. | FDA aligns with BioAtla on phase 3 trial design for cancer drug | 6 | Investing.com | ||
| 13.08. | BioAtla stock downgraded by Citizens JMP on cash concerns | 2 | Investing.com | ||
| 08.08. | BioAtla im August 2025: Vielversprechende klinische Daten treffen auf finanziellen Gegenwind | 4 | Investing.com Deutsch | ||
| 08.08. | BioAtla August 2025 slides: promising clinical data amid financial headwinds | 2 | Investing.com | ||
| 07.08. | BioAtla GAAP EPS of -$0.32 misses by $0.03 | 2 | Seeking Alpha | ||
| 07.08. | BioAtla, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,206 | +0,58 % | Evotec: Startet jetzt der Turnaround? | ||
| BB BIOTECH | 45,700 | -1,08 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| CUREVAC | 4,346 | -0,59 % | HV-Termine: Hauptversammlungen bei artnet, BVB, Cherry, CureVac, Schloss Wachenheim, SDM, The Grounds | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| MODERNA | 20,115 | -3,43 % | Biologische Fertigung im Fokus - wie NurExone, Moderna und Lonza von der Industrialisierung regenerativer Therapien profitieren könnten | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,600 | +4,58 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| INFLARX | 1,031 | +1,88 % | InflaRx reports positive phase 2 results for HS and CSU treatments | ||
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 3,047 | +0,46 % | Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? | ||
| BEAM THERAPEUTICS | 22,205 | +7,84 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,011 | +0,80 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,490 | -1,27 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Third Quarter 2025 Financial Results and Business Highlights | Recent Investor Day highlighted how AXPAXLI is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,404 | +0,89 % | CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald | ||
| CIDARA THERAPEUTICS | 189,00 | -1,05 % | Merck agrees deal with Cidara Therapeutics worth almost $9.2bn | ||
| SPERO THERAPEUTICS | 1,958 | -2,59 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen |
Das Unternehmen BIOATLA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,285 (-24,68 %) liegt der Kurs bei 0,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOATLA INC finden Sie auf Wallstreet Online.